Orphazyme A/SCompany announcement                                                                              No. 03/2021                                                                                                  Company Registration No. 32266355

Read the original here:
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities

Nicox SASociété anonyme with a registered capital of € 37,030,335

See more here:
Number of voting rights as of January 31, 2021

Regulated information — Inside information

See the article here:
argenx announces launch of proposed global offering

REDWOOD CITY, Calif. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the closing of an underwritten public offering of 3,750,000 shares of Class A common stock at a public offering price of $67.00 per share, before deducting underwriting discounts and commissions. Of the 3,750,000 shares sold in the offering, 1,650,000 were sold by Seer and 2,100,000 were sold by selling stockholders of Seer.

Read more:
Seer Announces Closing of Public Offering of Common Stock

BOSTON, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on January 29, 2021, the Company granted stock options and restricted stock units to 92 new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.

Read more:
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Ap9

More here:
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the retirement of Gary Sender as Chief Financial Officer (CFO), effective as of March 12, 2021. Mr. Sender has agreed to serve as a consultant for Nabriva on an ongoing basis following his retirement to ensure business continuity. Mr. Sender informed Nabriva that he plans to focus on his three public company Board roles and providing financial advisory services. A search has been initiated to identify a new CFO.

Read the original here:
Nabriva Therapeutics Announces Retirement of its Chief Financial Officer

PLEASANTON, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2020 after market close on Wednesday, February 17, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Read the original post:
10x Genomics to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021

Company Announcement

Original post:
Grant of Restricted Stock Units and Warrants to Employees in Genmab

NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity report for the second quarter ended December 31, 2020.

View post:
Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020

Follow this link:
Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021

AIM is Working to Develop an Effective COVID-19 Intranasal Therapy AIM is Working to Develop an Effective COVID-19 Intranasal Therapy

More:
AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen

Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board

See more here:
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board

TORONTO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce Greg Hunter will join MediPharm Labs as Chief Financial Officer (CFO), effective February 8, 2021.

Continued here:
MediPharm Labs Appoints New Chief Financial Officer

Commercial Launch of Libmeldy™ in Europe On-Track for 1H 2021 Commercial Launch of Libmeldy™ in Europe On-Track for 1H 2021

Visit link:
Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer

WALTHAM, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced the appointment of Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs.

Visit link:
OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs

The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is June 7, 2021

More here:
Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab

TORONTO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (“Psyence” or the “Company”) is pleased to announce that it has concluded its first cultivation and harvest cycle of natural medical psilocybin mushrooms. The mushrooms were grown, harvested, processed, and packed at its premium production facility in Lesotho which has been designed and built to the highest international standards.

Original post:
Psyence Group Completes First Cultivation Cycle of Medical Psilocybin Mushrooms at Its Commercially Licensed Facility

SAN DIEGO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced updated interim findings from the ongoing TRIDENT-1 registrational study of lead drug candidate repotrectinib in patients with ROS1-positive TKI-naïve non-small cell lung cancer (NSCLC).

View original post here:
Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive...

Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced with its affiliate Altamira Medica AG the initiation of a clinical investigation of AM-301 in allergic rhinitis.

More:
Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis